vincristine + irinotecan

Vincristine + irinotecan is a combination chemotherapy regimen consisting of two small molecule cytotoxic agents, vincristine and irinotecan. Vincristine is a vinca alkaloid that inhibits microtubule formation in mitotic spindle fibers, leading to cell cycle arrest at metaphase. Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and replication by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in double-strand breaks during DNA synthesis. This combination has been studied primarily for the treatment of relapsed or refractory rhabdomyosarcoma (RMS) and other pediatric solid tumors. The rationale for combining these drugs includes their non-overlapping toxicity profiles and potential synergistic antitumor effects[2][4][5]. The combination may be used alone (VI) or with temozolomide (VIT), but "vincristine + irinotecan" refers specifically to the two-drug regimen.

Other names

vincristine and irinotecanVI